Back to Treatments

Treatment

SGLT2 Inhibitors (e.g., Dapagliflozin)

2
Conditions
55
Trials
75K
Participants
65%
Average Safety

Condition Evidence

Chronic kidney disease due to hypertension

30 trials · 50K participants

95% effectiveness · 65% safety

Dilated Cardiomyopathy

25 trials · 25K participants

92% effectiveness · 65% safety
SGLT2 Inhibitors (e.g., Dapagliflozin) | DFDA